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Introduction
Even though rare, thymomas are the most common 
neoplasms arising from the thymic epithelium of the 
anterior mediastinum. With an incidence of 0.13 cases 
per 100,000 persons/year in the USA, they can occur in 
patients of any age but are very rare in the first 2 decades 
of life (1). The ratio of men to women in the published 
literature is roughly equal. Given the rarity of thymomas, 
the knowledge about the etiology is very limited. A causal 
relationship between tobacco, alcohol or environmental 
factors and an increased incidence of thymoma has never 
been demonstrated.
Histologically thymoma arises from thymic epithelial 
cells but contains a variable number of lymphocytes, which 
are not neoplastic.
Subtyping and classifying thymomas has represented a 
big challenge and indeed several pathologic, clinical and 
surgical classifications have been developed and published 
over the years. In 1961, Bernatz and colleagues classified 
thymoma based on the predominant lymphocytes and 
epithelial component (2).
Fifteen years later, Rosai and Levine (3) focused their 
attention on the presence or absence of invasiveness 
describing thymoma as (I) benign encapsulated thymoma, 
(II) type 1 malignant thymoma (invasive), and (III) type 2 
malignant thymoma (thymic carcinomas).
In 1985, Marino and Müller-Hermelink reported a new 
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classification according to the assumed localization of the 
malignant thymus cells including five subtypes: medullary, 
mixed, predominantly cortical, cortical thymomas, and well-
differentiated thymic carcinomas (4).
Nowadays, the WHO histologic classification along with 
Masaoka are the most broadly used classification systems for 
thymic epithelial tumors, providing a useful guidance for 
surgeons, oncologists and radiation oncologists in clinical 
decision-making (5-7).
Clinical features of thymoma
Clinical presentation of thymomas can vary from an 
incidental finding on chest radiography (Figure 1) or 
computed tomography (CT) scan (Figure 2), to symptoms 
deriving from mass effect in the mediastinum or from a 
systemic syndrome. About 30% of thymoma patients are 
asymptomatic and the diagnosis is made incidentally; maybe 
this percentage will continue to rise due to the increasing 
and widespread use of CT scans, also in the setting of lung 
cancer screening.
Up to 80% of thymomas are visible on chest radiography, 
although without any specific signs. Usually they present 
like an ovoid or lobulated, smooth, well-marginated 
mediastinal tumor, abutting unilaterally (rarely this mass 
may protrude bilaterally). In the lateral view such masses 
are often easily visible as an abnormal radiopacity in the 
retrosternal space (8). 
The typical CT features of thymoma (well defined 
and distinct from the surrounding mediastinal fat, round 
or lobulated, homogenous) are highly evocative of the 
diagnosis. Unlike other mediastinal tumors, thymomas are 
usually not associated with metastatic lymphadenopathy 
or with lung metastases. The use of intravenous contrast is 
not mandatory per se in order to characterize the thymic 
mass but it may certainly help in evaluating the invasiveness 
of the tumor in the preoperative staging and, therefore, 
therapeutic decision-making. 
The tumor is usually located ventral to the pericardium, 
aorta, pulmonary artery, or superior vena cava, despite 
thymomas have been reported in locations everywhere 
between the lower neck and the cardiophrenic space (8). 
The local tumor growth could trigger several symptoms 
due to compression and/or invasion of adjacent structures. 
However, even patients with invasive lesions tend to show 
a prolonged clinical course. The most common symptoms, 
although nonspecific, are chest discomfort/pain, cough 
and dyspnea. If thymoma has a more aggressive behavior 
growing abnormally, some unusual manifestations, such as 
superior vena cava syndrome and phrenic nerve paralysis, 
may be present. Stridor and dysphagia can be late signs, 
caused by compression of the trachea and/or esophagus.
The presence of pleural or pericardial effusion is very 
unusual and may suggest an advanced stage of the disease. 
Very rare, with few cases published in the literature, is 
the spontaneous rupture of thymoma as onset manifestation 
of the tumor (9-11) 
Myasthenia gravis
Thirty-five percent of patients with thymoma have myasthenia 
gravis (MG; from Greek: myos = muscle, asthenos = weakness, 
and Latin: gravis =severe), a complex autoimmune disorders 
Figure 1 Chest X-ray showing a mediastinal mass protruding to 
the right hemithorax.
Figure 2 Chest CT showing a mediastinal mass. CT, computed 
tomography.
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characterized by increasing muscle fatigability and weakness 
which involves skeletal muscles and is caused, in more than 
85% of cases, by circulating antibodies against nicotinic 
acetylcholine receptors (AChRs) (12). 
MG is an uncommon disease with a bimodal age-
related incidence peak (patients between 20–30 years and 
between 60–80 years) (13). The specific pathophysiologic 
mechanisms that lead to the AChRs antibodies production 
are not fully understood.  
The most likely hypothesis is that, in some patients, 
auto-reactive T cells can recruit AChR-responsive B 
cells, stimulating the production of pathogenic anti 
AChR antibodies. Consequently, the decreased number 
of functional AChRs causes a deficit in neuromuscular 
transmission (14). The reasons of the T cells deregulation 
remain unclear, even if Epstein-Barr virus infection has 
been postulated (15). However, 20% of patients with MG 
have no circulating antibodies against AChR but rather 
present antibodies against muscle specific tyrosine kinase 
(MuSK), a subclass of immunoglobulin G4. 
Up to 50% of patients with AChR and MuSK negative 
antibodies present anti-low-density lipoprotein receptor-
related protein 4 (Lrp4) antibodies, an immunoglobulin 
G1 subclass which inhibits the binding of their target with 
agrin, a protein which plays a key role in the structure and 
function of the neuromuscular junction.
The subtypization of the abovementioned antibodies is 
very important because symptom distribution and response to 
treatment differ between the various form of MG (Table 1) (14).
The symptomatology of MG consists mainly of voluntary 
muscles fluctuating weakness (Table 2). In an early phase, 
patients often complain of ocular muscle weakness with 
ptosis along with diplopia without deficits of sensorium. 
Most patients show a progress to generalized weakness 
during the first 2 years after the diagnosis. Fatigue of the 
proximal limbs muscles causes difficulties in climbing stairs 
and holding the arms above the head. 
Other potential involved muscles are the bulbar muscles, 
resulting in dysarthria, dysphagia, difficult mastication, and 
dyspnea.
Impairment of the facial muscles can produce the so 
called “hanging jaw sign” (because of the inability to 
hold the mouth closed) and the “myasthenic snarl” (when 
patients try to smile).
One of the very typical aspects of this disease is the 
fluctuation and variability of symptoms within a period 
of a day (muscle fatigability exacerbates in the evening), 
months or years. As such, patients can experience periods of 
remission and periods with severe exacerbations. 
The most feared complication of MG is a myasthenic 
crisis, often triggered by a respiratory infection or surgical 
procedures. The majority of patients with a myasthenic 
crisis must be admitted to an intensive care unit where the 
respiratory failure usually requires ventilatory assistance 
(non-invasive or with endotracheal intubation). The overall 
mortality of such a crisis has decreased in the past 50 years 
from 50% to 6%.
The diagnosis is nowadays made by detecting the 
presence of myasthenic antibodies in the serum, by 
performing electrophysiological tests such as single-fiber 
Table 1 Clinical subgroups of MG
MG subgroups Clinical features Genetic variant associated Antigen Thymus pathology
Early onset MG (EOMG) Age of presentation <50 years;  
rate female/male 3/1
HLA-B8, A1, DRw3 AChR Thymic lymphofollicular 
hyperplasia
Late onset MG (LOMG) Age of presentation >50 years;  
rate female/male 1/1.5 
HLA-A3, B7, DRw2 AChR Absence of thymus pathology
Thymoma-associated  
MG (TAMG)
Paraneoplastic MG – AChR Thymoma
Ocular MG (OMG) Ocular form – AChR Variable
MuSK MG Severe presentation, respiratory + bulbar 
muscle weakness; rate female/male 9/1
HLA-DR14-DQ5 MuSK Absence of thymus pathology 
Lrp4 MG Mild phenotype; rate female/male 2.5/1 – Lrp4 Variable 
Agrin MG General weakness, if additional AChR, 
MuSK, Lrp4 antibodies: severe weakness
– Agrin Absence of thymus pathology 
MG, myasthenia gravis; AChR, acetylcholine receptor; MuSK, muscle specific tyrosine kinase.
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Table 2 Myasthenia Gravis Foundation of America (MGFA) classification (16)
Class Clinical manifestation
Class I Any ocular muscle weakness
May have weakness of eye closure
All other muscle strength is normal
Class II Mild weakness affecting other than ocular muscles
May also have ocular muscle weakness of any severity
Class IIa Predominantly affecting limb, axial muscles, or both
may also have lesser involvement of oropharyngeal muscles
Class IIb Predominantly affecting oropharyngeal, respiratory muscles, or both
May also have lesser or equal involvement of limb, axial muscles, or both
Class III Moderate weakness affecting other than ocular muscles
May also have ocular muscle weakness of any severity
Class IIIa Predominantly affecting limb, axial muscles, or both
May also have lesser involvement of oropharyngeal muscles
Class IIIb Predominantly affecting oropharyngeal, respiratory muscles, or both
May also have lesser or equal involvement of limb, axial muscles, or both
Class IV Severe weakness affecting other than ocular muscles
May also have ocular muscle weakness of any severity
Class IVa Predominantly affecting limb and/or axial muscles
May also have lesser involvement of oropharyngeal muscles
Class IVb Predominantly affecting oropharyngeal, respiratory muscles, or both
May also have lesser or equal involvement of limb, axial muscles, or both
Class V Defined by intubation, with or without mechanical ventilation, except during post-operative management. The use of 
feeding tube without intubation places the patient in class IVb
electromyography (SFEMG), and by repetitive nerve 
stimulation (RNS). Suppression of acetylcholinesterase 
(AChE) with pyridostigmine or ice pack test, which 
normally ameliorates the symptoms, have been widely used.
All patients with MG should be screened with a CT scan 
of the chest searching for possible thymic hyperplasia or 
tumors. In case of radiologically suspect features, a biopsy 
should be avoided due to the risk of exacerbating the disease 
as well as to prevent potential spilling/seeding of tumor 
cells. 
An interdisciplinary discussion amongst neurologist and 
thoracic surgeon is of the essence when evaluating treatment 
options (anticholinesterase agents, immunosuppressants, 
plasmapheresis, immunoglobulin, thymectomy) and their 
sequence. 
Paraneoplastic disorders
It has been reported that 95% of thymomas show an 
absence of autoimmune regulator (AIRE) expression along 
with reduced major histocompatibility complex (MHC) 
class II expression, suggesting that dysregulation of T cell 
growth is one of the main factors in the pathogenesis of 
paraneoplastic disorders in thymoma (17).
Besides MG, other syndromes commonly associated 
with thymoma (2–6%) are pure red cell aplasia and 
hypogammaglobulinemia. Patients who present with these 
paraneoplastic conditions should always undergo a chest 
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CT scan to rule out a thymoma as primum movens.
Pure red cell aplasia is a rare condition caused by 
severe normocytic anemia, reticulocytopenia and absence 
of erythroblasts in the bone marrow, and can only be 
found in a small percentage of patients with thymoma. 
Surgical thymectomy is usually indicated in these patients 
even if the initial remission rate is only 30% and an 
additional treatment with corticosteroids, cyclosporine, or 
cyclophosphamide is therefore mandatory in most patients. 
Hypogammaglobulinemia, also known as Good’s syndrome, 
is a rare combined T- and B-cell immunodeficiency, which 
renders patients highly susceptible to bacterial, viral, fungal 
and opportunistic infections. To date the pathophysiology of 
the disease is not fully understood but in published case series 
thymoma was an incidental finding on chest radiograph or CT 
scan in 10–41% of patients (18,19).
Another possible rare presentation of thymoma is a type 
of paraneoplastic syndrome that resembles Graft-versus-host 
disease (GvHD). This syndrome has also been described 
as “thymoma associated multiorgan autoimmunity” 
(TAMA) and involves the skin, liver and intestines (20,21). 
Typical clinical manifestations of TAMA include confluent 
keratotic papules, scaly plaques, morbilliform eruptions, 
erythroderma and mucosal erosions, diarrhea and abnormal 
liver enzyme levels, especially alkaline phosphatase.
Despi te  the  fact  that  progress  has  been made 
regarding the understanding of thymoma and associated 
paraneoplastic diseases, the gold standard management of 
affected patients remains unknown.
Conclusions
Given the variability of thymoma clinical presentations, a 
high index of suspicion is required in order to establish the 
right diagnosis. Understanding the role of the thymus in 
the pathophysiology of different autoimmune diseases may 
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